Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 137


Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model.

Maguire SL, Peck B, Wai PT, Campbell J, Barker H, Gulati A, Daley F, Vyse S, Huang P, Lord CJ, Farnie G, Brennan K, Natrajan R.

J Pathol. 2016 Nov;240(3):315-328. doi: 10.1002/path.4778.


Synthetic lethality: the road to novel therapies for breast cancer.

Dhillon KK, Bajrami I, Taniguchi T, Lord CJ.

Endocr Relat Cancer. 2016 Oct;23(10):T39-55. doi: 10.1530/ERC-16-0228. Review.


Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib.

Miller RE, Brough R, Bajrami I, Williamson CT, McDade S, Campbell J, Kigozi A, Rafiq R, Pemberton H, Natrajan R, Joel J, Astley H, Mahoney C, Moore JD, Torrance C, Gordan JD, Webber JT, Levin RS, Shokat KM, Bandyopadhyay S, Lord CJ, Ashworth A.

Mol Cancer Ther. 2016 Jul;15(7):1472-84. doi: 10.1158/1535-7163.MCT-15-0554.


Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell Lymphoma.

Beck D, Zobel J, Barber R, Evans S, Lezina L, Allchin RL, Blades M, Elliott R, Lord CJ, Ashworth A, Porter AC, Wagner SD.

J Biol Chem. 2016 Aug 5;291(32):16686-98. doi: 10.1074/jbc.M116.736868.


Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.

Costa-Cabral S, Brough R, Konde A, Aarts M, Campbell J, Marinari E, Riffell J, Bardelli A, Torrance C, Lord CJ, Ashworth A.

PLoS One. 2016 Apr 18;11(4):e0154007. doi: 10.1371/journal.pone.0154007. No abstract available.


Overexpression of MYB drives proliferation of CYLD-defective cylindroma cells.

Rajan N, Andersson MK, Sinclair N, Fehr A, Hodgson K, Lord CJ, Kazakov DV, Vanecek T, Ashworth A, Stenman G.

J Pathol. 2016 Jun;239(2):197-205. doi: 10.1002/path.4717.


Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines.

Campbell J, Ryan CJ, Brough R, Bajrami I, Pemberton HN, Chong IY, Costa-Cabral S, Frankum J, Gulati A, Holme H, Miller R, Postel-Vinay S, Rafiq R, Wei W, Williamson CT, Quigley DA, Tym J, Al-Lazikani B, Fenton T, Natrajan R, Strauss SJ, Ashworth A, Lord CJ.

Cell Rep. 2016 Mar 15;14(10):2490-501. doi: 10.1016/j.celrep.2016.02.023.


CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.

Costa-Cabral S, Brough R, Konde A, Aarts M, Campbell J, Marinari E, Riffell J, Bardelli A, Torrance C, Lord CJ, Ashworth A.

PLoS One. 2016 Feb 16;11(2):e0149099. doi: 10.1371/journal.pone.0149099. Erratum in: PLoS One. 2016;11(4):e0154007.


BRCAness revisited.

Lord CJ, Ashworth A.

Nat Rev Cancer. 2016 Feb;16(2):110-20. doi: 10.1038/nrc.2015.21. Review.


DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, Boysen G, Porta N, Flohr P, Gillman A, Figueiredo I, Paulding C, Seed G, Jain S, Ralph C, Protheroe A, Hussain S, Jones R, Elliott T, McGovern U, Bianchini D, Goodall J, Zafeiriou Z, Williamson CT, Ferraldeschi R, Riisnaes R, Ebbs B, Fowler G, Roda D, Yuan W, Wu YM, Cao X, Brough R, Pemberton H, A'Hern R, Swain A, Kunju LP, Eeles R, Attard G, Lord CJ, Ashworth A, Rubin MA, Knudsen KE, Feng FY, Chinnaiyan AM, Hall E, de Bono JS.

N Engl J Med. 2015 Oct 29;373(18):1697-708. doi: 10.1056/NEJMoa1506859.


Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.

Kwon YJ, Petrie K, Leibovitch BA, Zeng L, Mezei M, Howell L, Gil V, Christova R, Bansal N, Yang S, Sharma R, Ariztia EV, Frankum J, Brough R, Sbirkov Y, Ashworth A, Lord CJ, Zelent A, Farias E, Zhou MM, Waxman S.

Mol Cancer Ther. 2015 Aug;14(8):1824-36. doi: 10.1158/1535-7163.MCT-14-0980-T.


Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway.

Conti A, Majorini MT, Elliott R, Ashworth A, Lord CJ, Cancelliere C, Bardelli A, Seneci P, Walczak H, Delia D, Lecis D.

Oncotarget. 2015 May 10;6(13):10994-1008.


Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity.

Frankum J, Moudry P, Brough R, Hodny Z, Ashworth A, Bartek J, Lord CJ.

Oncotarget. 2015 May 10;6(13):10746-58.


Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers.

Watkins J, Weekes D, Shah V, Gazinska P, Joshi S, Sidhu B, Gillett C, Pinder S, Vanoli F, Jasin M, Mayrhofer M, Isaksson A, Cheang MC, Mirza H, Frankum J, Lord CJ, Ashworth A, Vinayak S, Ford JM, Telli ML, Grigoriadis A, Tutt AN.

Cancer Discov. 2015 May;5(5):488-505. doi: 10.1158/2159-8290.CD-14-1092.


Whole-exome DNA sequence analysis of Brca2- and Trp53-deficient mouse mammary gland tumours.

Francis JC, Melchor L, Campbell J, Kendrick H, Wei W, Armisen-Garrido J, Assiotis I, Chen L, Kozarewa I, Fenwick K, Swain A, Smalley MJ, Lord CJ, Ashworth A.

J Pathol. 2015 Jun;236(2):186-200. doi: 10.1002/path.4517.


Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways.

Aarts M, Bajrami I, Herrera-Abreu MT, Elliott R, Brough R, Ashworth A, Lord CJ, Turner NC.

Mol Cancer Ther. 2015 Apr;14(4):865-76. doi: 10.1158/1535-7163.MCT-14-0845.


The cylindromatosis gene product, CYLD, interacts with MIB2 to regulate notch signalling.

Rajan N, Elliott RJ, Smith A, Sinclair N, Swift S, Lord CJ, Ashworth A.

Oncotarget. 2014 Dec 15;5(23):12126-40.


Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors.

Lord CJ, Tutt AN, Ashworth A.

Annu Rev Med. 2015;66:455-70. doi: 10.1146/annurev-med-050913-022545. Review.


DAISY: picking synthetic lethals from cancer genomes.

Ryan CJ, Lord CJ, Ashworth A.

Cancer Cell. 2014 Sep 8;26(3):306-8. doi: 10.1016/j.ccr.2014.08.008.


Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signaling.

Gao S, Bajrami I, Verrill C, Kigozi A, Ouaret D, Aleksic T, Asher R, Han C, Allen P, Bailey D, Feller S, Kashima T, Athanasou N, Blay JY, Schmitz S, Machiels JP, Upile N, Jones TM, Thalmann G, Ashraf SQ, Wilding JL, Bodmer WF, Middleton MR, Ashworth A, Lord CJ, Macaulay VM.

Cancer Res. 2014 Oct 15;74(20):5866-77. doi: 10.1158/0008-5472.CAN-14-0806.

Items per page

Supplemental Content

Support Center